Scarica l'app Stockscreener
11.04
5.96%
-0.70
Precedente Chiudi:
$11.74
Aprire:
$11.87
Volume 24 ore:
98,433
Relative Volume:
0.93
Capitalizzazione di mercato:
$289.81M
Reddito:
$59,000
Utile/perdita netta:
$-21.81M
Rapporto P/E:
-1.0081
EPS:
-10.9518
Flusso di cassa netto:
$-18.07M
1 W Prestazione:
-13.62%
1M Prestazione:
-26.10%
6M Prestazione:
+7.18%
1 anno Prestazione:
+14.40%
Intervallo 1D:
$11.03
$11.96
Intervallo di 1 settimana:
$11.03
$13.27
Portata 52W:
$7.05
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
Nome
Benitec Biopharma Inc
Settore
Industria
Telefono
(510) 780-0819
Indirizzo
3940 TRUST WAY, HAYWARD, CA
Confronta BNTC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
11.04 | 335.48M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-07 | Iniziato | TD Cowen | Buy |
| 2024-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-10-16 | Iniziato | Oppenheimer | Outperform |
| 2024-09-12 | Iniziato | Guggenheim | Buy |
| 2024-07-22 | Iniziato | Leerink Partners | Outperform |
| 2024-06-13 | Iniziato | Piper Sandler | Overweight |
| 2020-10-05 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-04-20 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-02-26 | Downgrade | Maxim Group | Buy → Hold |
| 2015-12-31 | Reiterato | Maxim Group | Buy |
| 2015-09-16 | Reiterato | Maxim Group | Buy |
Mostra tutto
Benitec Biopharma Inc Borsa (BNTC) Ultime notizie
Is Benitec Biopharma Inc. a good long term investmentUnrivaled growth potential - jammulinksnews.com
What drives Benitec Biopharma Inc. stock priceMarket-crushing stock picks - PrintWeekIndia
What analysts say about Benitec Biopharma Inc. stockFree Stock Market Mentorship - Autocar Professional
(BNTC) Investment Report - news.stocktradersdaily.com
Benitec Biopharma Inc. Stock Analysis and ForecastOutstanding capital appreciation - jammulinksnews.com
Does Benitec Biopharma Inc. stock pay reliable dividendsFree Investment Community - Newser
Benitec Biopharma Limited (NASDAQ:BNTC) Given Average Recommendation of “Buy” by Analysts - Defense World
What analysts say about Benitec Biopharma Inc. stock outlookSmart High Yield Swing Trades - Newser
Why Benitec Biopharma Inc. stock attracts strong analyst attentionLong Term Safe Yield Focus - beatles.ru
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise amid trial progress - Investing.com Australia
What makes Benitec Biopharma Inc. stock price move sharplyTriple Digit Return Forecasts - Newser
How Benitec Biopharma Inc. stock performs during market volatilityFree Stock Market Forecasting Tools - Newser
Citizens JMP Reaffirms Their Buy Rating on Benitec Biopharma (BNTC) - The Globe and Mail
Benitec BioPharma stock maintains Market Outperform rating at JMP By Investing.com - Investing.com Canada
Benitec completes first cohort in gene therapy trial, advances to next phase By Investing.com - Investing.com South Africa
When the Price of (BNTC) Talks, People Listen - news.stocktradersdaily.com
Benitec Biopharma Advances BB-301 Clinical Study - TipRanks
Benitec Biopharma Provides Operational Updates - GlobeNewswire
Benitec Biopharma Inc. Provides Operational Updates - MarketScreener
Benitec Biopharma (BNTC) Moves Forward with Clinical Study Enrollment | BNTC Stock News - GuruFocus
Benitec completes first cohort in gene therapy trial, advances to next phase - Investing.com
Benitec's BB-301 Gene Therapy Achieves Key Safety Milestone, Phase 1b/2a Trial Set to Expand - Stock Titan
Benitec Biopharma (NASDAQ:BNTC) Now Covered by Analysts at TD Cowen - Defense World
Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 3000 Index - MarketScreener
Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 3000 Growth Index - MarketScreener
Benitec Biopharma(BNTC) Plunges 8.10% on Earnings Concerns - AInvest
Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Trading (BNTC) With Integrated Risk Controls - news.stocktradersdaily.com
GAMMA Investing LLC Grows Stake in Benitec Biopharma Inc. (NASDAQ:BNTC) - Defense World
Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable - Nasdaq
(BNTC) Trading Report - news.stocktradersdaily.com
Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High? - Yahoo Finance
Benitec Biopharma Inc. (NASDAQ:BNTC) Position Boosted by Ameriprise Financial Inc. - Defense World
Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Form 424B3 Benitec Biopharma Inc. - StreetInsider
Northern Trust Corp Grows Stock Holdings in Benitec Biopharma Inc. (NASDAQ:BNTC) - Defense World
Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why - Yahoo Finance
Benitec Biopharma Inc Azioni (BNTC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Benitec Biopharma Inc Azioni (BNTC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Mar 26 '25 |
Buy |
13.00 |
900,000 |
11,700,000 |
8,793,245 |
| BUCHI J KEVIN | Director |
Feb 27 '25 |
Option Exercise |
3.86 |
51,813 |
199,998 |
103,910 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '24 |
Buy |
10.98 |
27,502 |
301,972 |
7,981,725 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 24 '24 |
Buy |
11.25 |
20,018 |
225,202 |
7,999,455 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 03 '24 |
Buy |
9.60 |
42,000 |
403,200 |
7,957,365 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 20 '24 |
Buy |
10.22 |
27,436 |
280,396 |
7,920,175 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 19 '24 |
Buy |
9.73 |
14,000 |
136,220 |
7,895,815 |
0.59%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):